Cargando…

Putatively novel serotypes and the potential for reduced vaccine effectiveness: capsular locus diversity revealed among 5405 pneumococcal genomes

The pneumococcus is a leading global pathogen and a key virulence factor possessed by the majority of pneumococci is an antigenic polysaccharide capsule (‘serotype’), which is encoded by the capsular (cps) locus. Approximately 100 different serotypes are known, but the extent of sequence diversity w...

Descripción completa

Detalles Bibliográficos
Autores principales: van Tonder, Andries J., Bray, James E., Quirk, Sigríður J., Haraldsson, Gunnsteinn, Jolley, Keith A., Maiden, Martin C. J., Hoffmann, Steen, Bentley, Stephen D., Haraldsson, Ásgeir, Erlendsdóttir, Helga, Kristinsson, Karl G., Brueggemann, Angela B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Microbiology Society 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266551/
https://www.ncbi.nlm.nih.gov/pubmed/28133541
http://dx.doi.org/10.1099/mgen.0.000090
_version_ 1782500484728225792
author van Tonder, Andries J.
Bray, James E.
Quirk, Sigríður J.
Haraldsson, Gunnsteinn
Jolley, Keith A.
Maiden, Martin C. J.
Hoffmann, Steen
Bentley, Stephen D.
Haraldsson, Ásgeir
Erlendsdóttir, Helga
Kristinsson, Karl G.
Brueggemann, Angela B.
author_facet van Tonder, Andries J.
Bray, James E.
Quirk, Sigríður J.
Haraldsson, Gunnsteinn
Jolley, Keith A.
Maiden, Martin C. J.
Hoffmann, Steen
Bentley, Stephen D.
Haraldsson, Ásgeir
Erlendsdóttir, Helga
Kristinsson, Karl G.
Brueggemann, Angela B.
author_sort van Tonder, Andries J.
collection PubMed
description The pneumococcus is a leading global pathogen and a key virulence factor possessed by the majority of pneumococci is an antigenic polysaccharide capsule (‘serotype’), which is encoded by the capsular (cps) locus. Approximately 100 different serotypes are known, but the extent of sequence diversity within the cps loci of individual serotypes is not well understood. Investigating serotype-specific sequence variation is crucial to the design of sequence-based serotyping methodology, understanding pneumococcal conjugate vaccine (PCV) effectiveness and the design of future PCVs. The availability of large genome datasets makes it possible to assess population-level variation among pneumococcal serotypes and in this study 5405 pneumococcal genomes were used to investigate cps locus diversity among 49 different serotypes. Pneumococci had been recovered between 1916 and 2014 from people of all ages living in 51 countries. Serotypes were deduced bioinformatically, cps locus sequences were extracted and variation was assessed within the cps locus, in the context of pneumococcal genetic lineages. Overall, cps locus sequence diversity varied markedly: low to moderate diversity was revealed among serogroups/types 1, 3, 7, 9, 11 and 22; whereas serogroups/types 6, 19, 23, 14, 15, 18, 33 and 35 displayed high diversity. Putative novel and/or hybrid cps loci were identified among all serogroups/types apart from 1, 3 and 9. This study demonstrated that cps locus sequence diversity varied widely between serogroups/types. Investigation of the biochemical structure of the polysaccharide capsule of major variants, particularly PCV-related serotypes and those that appear to be novel or hybrids, is warranted.
format Online
Article
Text
id pubmed-5266551
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Microbiology Society
record_format MEDLINE/PubMed
spelling pubmed-52665512017-01-25 Putatively novel serotypes and the potential for reduced vaccine effectiveness: capsular locus diversity revealed among 5405 pneumococcal genomes van Tonder, Andries J. Bray, James E. Quirk, Sigríður J. Haraldsson, Gunnsteinn Jolley, Keith A. Maiden, Martin C. J. Hoffmann, Steen Bentley, Stephen D. Haraldsson, Ásgeir Erlendsdóttir, Helga Kristinsson, Karl G. Brueggemann, Angela B. Microb Genom BioResource The pneumococcus is a leading global pathogen and a key virulence factor possessed by the majority of pneumococci is an antigenic polysaccharide capsule (‘serotype’), which is encoded by the capsular (cps) locus. Approximately 100 different serotypes are known, but the extent of sequence diversity within the cps loci of individual serotypes is not well understood. Investigating serotype-specific sequence variation is crucial to the design of sequence-based serotyping methodology, understanding pneumococcal conjugate vaccine (PCV) effectiveness and the design of future PCVs. The availability of large genome datasets makes it possible to assess population-level variation among pneumococcal serotypes and in this study 5405 pneumococcal genomes were used to investigate cps locus diversity among 49 different serotypes. Pneumococci had been recovered between 1916 and 2014 from people of all ages living in 51 countries. Serotypes were deduced bioinformatically, cps locus sequences were extracted and variation was assessed within the cps locus, in the context of pneumococcal genetic lineages. Overall, cps locus sequence diversity varied markedly: low to moderate diversity was revealed among serogroups/types 1, 3, 7, 9, 11 and 22; whereas serogroups/types 6, 19, 23, 14, 15, 18, 33 and 35 displayed high diversity. Putative novel and/or hybrid cps loci were identified among all serogroups/types apart from 1, 3 and 9. This study demonstrated that cps locus sequence diversity varied widely between serogroups/types. Investigation of the biochemical structure of the polysaccharide capsule of major variants, particularly PCV-related serotypes and those that appear to be novel or hybrids, is warranted. Microbiology Society 2016-10-21 /pmc/articles/PMC5266551/ /pubmed/28133541 http://dx.doi.org/10.1099/mgen.0.000090 Text en © 2016 The Authors http://creativecommons.org/licenses/by/4.0/http://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the Creative Commons Attribution 4.04.0 International License (http://creativecommons.org/licenses/by/4.0/http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
spellingShingle BioResource
van Tonder, Andries J.
Bray, James E.
Quirk, Sigríður J.
Haraldsson, Gunnsteinn
Jolley, Keith A.
Maiden, Martin C. J.
Hoffmann, Steen
Bentley, Stephen D.
Haraldsson, Ásgeir
Erlendsdóttir, Helga
Kristinsson, Karl G.
Brueggemann, Angela B.
Putatively novel serotypes and the potential for reduced vaccine effectiveness: capsular locus diversity revealed among 5405 pneumococcal genomes
title Putatively novel serotypes and the potential for reduced vaccine effectiveness: capsular locus diversity revealed among 5405 pneumococcal genomes
title_full Putatively novel serotypes and the potential for reduced vaccine effectiveness: capsular locus diversity revealed among 5405 pneumococcal genomes
title_fullStr Putatively novel serotypes and the potential for reduced vaccine effectiveness: capsular locus diversity revealed among 5405 pneumococcal genomes
title_full_unstemmed Putatively novel serotypes and the potential for reduced vaccine effectiveness: capsular locus diversity revealed among 5405 pneumococcal genomes
title_short Putatively novel serotypes and the potential for reduced vaccine effectiveness: capsular locus diversity revealed among 5405 pneumococcal genomes
title_sort putatively novel serotypes and the potential for reduced vaccine effectiveness: capsular locus diversity revealed among 5405 pneumococcal genomes
topic BioResource
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266551/
https://www.ncbi.nlm.nih.gov/pubmed/28133541
http://dx.doi.org/10.1099/mgen.0.000090
work_keys_str_mv AT vantonderandriesj putativelynovelserotypesandthepotentialforreducedvaccineeffectivenesscapsularlocusdiversityrevealedamong5405pneumococcalgenomes
AT brayjamese putativelynovelserotypesandthepotentialforreducedvaccineeffectivenesscapsularlocusdiversityrevealedamong5405pneumococcalgenomes
AT quirksigriðurj putativelynovelserotypesandthepotentialforreducedvaccineeffectivenesscapsularlocusdiversityrevealedamong5405pneumococcalgenomes
AT haraldssongunnsteinn putativelynovelserotypesandthepotentialforreducedvaccineeffectivenesscapsularlocusdiversityrevealedamong5405pneumococcalgenomes
AT jolleykeitha putativelynovelserotypesandthepotentialforreducedvaccineeffectivenesscapsularlocusdiversityrevealedamong5405pneumococcalgenomes
AT maidenmartincj putativelynovelserotypesandthepotentialforreducedvaccineeffectivenesscapsularlocusdiversityrevealedamong5405pneumococcalgenomes
AT hoffmannsteen putativelynovelserotypesandthepotentialforreducedvaccineeffectivenesscapsularlocusdiversityrevealedamong5405pneumococcalgenomes
AT bentleystephend putativelynovelserotypesandthepotentialforreducedvaccineeffectivenesscapsularlocusdiversityrevealedamong5405pneumococcalgenomes
AT haraldssonasgeir putativelynovelserotypesandthepotentialforreducedvaccineeffectivenesscapsularlocusdiversityrevealedamong5405pneumococcalgenomes
AT erlendsdottirhelga putativelynovelserotypesandthepotentialforreducedvaccineeffectivenesscapsularlocusdiversityrevealedamong5405pneumococcalgenomes
AT kristinssonkarlg putativelynovelserotypesandthepotentialforreducedvaccineeffectivenesscapsularlocusdiversityrevealedamong5405pneumococcalgenomes
AT brueggemannangelab putativelynovelserotypesandthepotentialforreducedvaccineeffectivenesscapsularlocusdiversityrevealedamong5405pneumococcalgenomes